Background Medication-induced salivary gland dysfunction (MISGD), xerostomia (sensation
of oral dryness), and subjective sialorrhea cause significant morbidity and impair quality of …

Over a third of patients with major depressive disorder (MDD) do not have an adequate
response to first-line antidepressant treatments, ie, they have treatment-resistant depression …

Despite considerable progress in pharmacotherapy over the past seven decades, many
mental disorders remain insufficiently treated. This situation is in part due to the limited …

Objective: Major depressive disorder has been associated with dysregulation of the
endogenous opioid system. The authors sought to determine whether opioid modulation …

Abstract Proof-of-concept (POC) clinical trials play an important role in developing novel
treatments and determining whether existing treatments may be efficacious in broader …

Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to
huge impacts on direct and indirect personal and public medical costs. To overcome such a …

Less than one third of patients who suffer from major depressive disorder (MDD) report
remission following antidepressant treatments requiring more diverse treatment approaches …

Major depressive disorder (MDD) is associated with a significant burden and costs to the
society. As remission of depressive symptoms is achieved in only one-third of the MDD …

Objective: To review factors influencing placebo response and clinical trial outcome in
depression, and suggest ways to optimize trial success in mood disorders. Data Sources …

Randomized clinical trials in many conditions such as mental illness, pain, addiction, allergy
and asthma are subject to moderate-to-high rates of placebo response. This reduces the …